Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
This trial studies the side effects of sirolimus and durvalumab and to see how well they work
in treating patients with stage I-IIIA non-small cell lung cancer. Sirolimus is an oral
medication that blocks the mTOR cellular pathway which may help the immune system work
better. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Giving sirolimus before durvalumab may help the immune system get rid of cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Durvalumab Immunoglobulin G Immunoglobulins Sirolimus